Treatments for Pulmonary Hypertension: Sitaxsentan/Ambrisentan (Endothelin Receptors)

LUNG (PULMONARY): MAIN MENU

Pulmonary Hypertension: MAIN MENU

What is PH?
Primary PH
Isolated PH
Secondary PH

Exercised Induced PH
PH Disease Correlations
Symptoms
Diagnosis

Prognosis
Treatments
Research Registries

Research
Patient Support Organizations
Personal Stories

Treatments for Pulmonary Hypertension

Bosentan/Tracleer
Endothelin Receptors (Sitaxsentan/Ambrisentan)
Inhaled Prostacyclin (Ventavis, Iloprost)
Heart/Lung Transplants

Prostacyclin (Flolan, Epoprostenol) Warning
Sildenafil Citrate (Revatio, Viagra)
Stem Cell Transplant
Warfarin (Coumadin)

Treatments for Pulmonary Hypertension: Sitaxsentan/Ambrisentan (Endothelin Receptors)

The Effects Of Sitaxentan In Scleroderma-Associated Pulmonary Arterial Hypertension (SSc-PAH) Are Analogous To Those Seen In Idiopathic Pulmonary Arterial Hypertension (iPAH) The response to sitaxentan monotherapy over 1 year was similar between SSc-PAH and iPAH patients, despite baseline differences including worse baseline 6MWD in SSc-PAH and more SSc-PAH patients in FC II. Overall, sitaxentan was well tolerated and effective in SSc-PAH. However, patients with SSc-PAH may do better if detected early (before 6MWD is so reduced), so a high awareness from rheumatologists is paramount. J.E. Pope. SAT0218. EULAR 2008.

Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). Sitaxsentan appears to be efficacious in patients with PAH associated with CTD. Annals of the Rheumatic Diseases 2007;66:1467-1472.

FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial Hypertension (PAH). The U.S. Food and Drug Administration today approved Letairis (ambrisentan) for the treatment of PAH. Letairis significantly improved physical activity capacity compared with a placebo, as shown by a six-minute walk, a standard test. Letairis also delayed the worsening of the pulmonary hypertension. FDA News. 06/15/07.

Sitaxsentan, a Selective Endothelin-A Receptor Antagonist, Improves Exercise Capacity in PAH Associated with CTD. Sitaxsentan 100 mg improves the 6-minute walk diagnostic in patients with PAH-CTD with a low incidence of abnormal liver function tests. J. R. Seibold. SAT0233 EULAR 2006. (Also see: Dr. J.R. Seibold)